Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Mikael Lindstam

Chairperson of the Board

  • Bert Junno

Board

  • Åsa Kornfeld
  • Cristina Glad
  • Jan Nilsson
  • Johan Lindh
  • Theresa Comiskey Olsen
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Aptahem l Analyst Group intervjuar VD Mikael Lindstam om Q3 2022

    210827 APTAHEM INTERVJU

    Aptahem | CSO Presentation

    Intervju med Aptahems VD Mikael Lindstam

    Upcoming reports

    • 2023-05-11 Delårsrapport 2023-Q1

    • 2023-06-01 Årsstämma 2022

    • 2023-08-31 Delårsrapport 2023-Q2

    • 2023-10-26 Delårsrapport 2023-Q3

    • 2024-02-16 Bokslutskommuniké 2023

    Annual reports, prospectus etc.

    Technical analysis

    APTA- 2019-03-25

    Technical analysis

    APTA- 2019-02-11

    Technical analysis

    APTA- 2019-01-21

    Technical analysis

    APTA- 2018-11-22